Key result
Phosphodiesterase inhibitors modulate cyclic nucleotide pathways in corticostriatal and hippocampal circuits, offering potential therapeutic targets for neuropsychiatric disorders.
Answers are grounded in this paper and cite their sources.
This review summarizes the mechanisms and clinical status of PDE inhibitors in modulating corticostriatal and hippocampal circuits for neuropsychiatric disorders.
The corticostriatal and hippocampal circuits contribute to the neurobiological underpinnings of several neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia. Based on biological function, these circuits can be clustered into motor circuits, associative/cognitive circuits and limbic circuits. Together, dysfunctions in these circuits produce the wide range of symptoms observed in related neuropsychiatric disorders. Intracellular signaling in these circuits is largely mediated through the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway with an additional role for the cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG) pathway, both of which can be regulated by phosphodiesterase inhibitors (PDE inhibitors). Through their effects on cAMP response element-binding protein (CREB) and Dopamine- and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32), cyclic nucleotide pathways are involved in synaptic transmission, neuron excitability, neuroplasticity and neuroprotection. In this clinical review, we provide an overview of the current clinical status, discuss the general mechanism of action of PDE inhibitors in relation to the corticostriatal and hippocampal circuits and consider several translational challenges.
No takes yet. Share an insight, caveat, or question.
Heckman et al. (2018) conducted a review in Neuropsychiatric disorders (Alzheimer's disease, Parkinson's disease, schizophrenia). Phosphodiesterase inhibitors (PDE inhibitors) was evaluated. Phosphodiesterase inhibitors modulate cyclic nucleotide pathways in corticostriatal and hippocampal circuits, offering potential therapeutic targets for neuropsychiatric disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: